Safety of MF59™ adjuvant

This publication has 59 references indexed in Scilit:

• The perfect mix: recent progress in adjuvant research
  Nature Reviews Microbiology, 2007
• Acute disseminated encephalomyelitis
  Neurology, 2007
• Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene
  Clinical and Vaccine Immunology, 2006
• A universal vaccine for serogroup B meningococcus
  Proceedings of the National Academy of Sciences, 2006
• Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy
  The Journal of Infectious Diseases, 2005
• Human Immunodeficiency Virus Type 1 (HIV‐1) gp120–Specific Antibodies in Neonates Receiving an HIV‐1 Recombinant gp120 Vaccine
  The Journal of Infectious Diseases, 2001
• Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis
  European Journal of Immunology, 2001
• Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
  The Lancet, 2001
• A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais
  Vaccine, 2000
• Development of an Adjuvant to Enhance the Immune Response to Influenza Vaccine in the Elderly
  Biologicals, 1997